key: cord-0831029-wds48jq5 authors: Jhaveri, Ravi title: The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World date: 2021-03-23 journal: Clin Ther DOI: 10.1016/j.clinthera.2021.03.007 sha: 63f98ed3ad90682837f1c2f094a5d739613960e7 doc_id: 831029 cord_uid: wds48jq5 The approval of the COVID-19 mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization and several other vaccines likely to follow. These vaccines all utilize relatively new vaccine production platforms to produce the SARS-CoV2 Spike protein. This review discusses how these platforms work, what advantages they offer and the gaps that remain in public health efforts to control the COVID-19 pandemic. Currently, the COVID-19 pandemic has reached a next phase that brings much cause for optimism. New cases are on the decline after a massive winter peak, schools and businesses are reopening in various parts of the country and both versions of the mRNA vaccines are finding their way into many communities and settings for distribution. As of February 26, 2021 , the CDC reported that over 70 million doses have been administered to more than 22 million adults receiving the 2-dose series.[ https://covid.cdc.gov/covid-data-tracker/#vaccinations] However, there is still a long way to go before the US and the rest of the world achieves the estimated threshold of 70-80% vaccinated for herd immunity against SARS-CoV2 to controls pandemic spread (1) . With the ongoing challenges of supplying both versions of the mRNA vaccines, it is welcome news that several other vaccine candidates are reaching the point of late phase 3 testing and/or emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA). The first review in Clinical Therapeutics covered the background of traditional vaccine approval, the EUA process and details about the 2 mRNA vaccines (2) . This review will focus on 3 other versions of COVID-19 vaccines that represent new technologies for delivery of the SARS-CoV2 Spike protein antigen: recombinant adenovirus 2-dose version (Oxford/AstraZeneca), recombinant adenovirus 1-dose version (Janssen/ Johnson & Johnson) , recombinant Baculovirusexpression system (Novavax). They represent the potential for new populations who could receive vaccine, but also present production and perception challenges as these versions become ready for distribution. Table 1 summarizes the key information for the 5 SARS-CoV2 vaccines discussed in this article and the prior review. To reiterate briefly, all versions of COVID-19 vaccines contain amino acid substitutions that lock the SARS-CoV2 Spike protein in the pre-fusion conformation (2) . This is a required change to generate a protective antibody response. This version of the vaccine is a replication-defective chimpanzee adenovirus construct that encodes for the SARS-CoV2 Spike protein (3) . Recombinant virus expressing the Spike protein can be delivered to immune cells but cannot generate any new virus (Figure 1 ). This version was granted EUA in the UK on December 30, 2020 after release of phase 3 trial results and in the midst of a surge in cases caused by a new variant with increased transmission efficiency (4) . As mentioned in the prior review, the primary purpose of this version of vaccine was to create a low cost option (estimated $3/dose) that could be produced and distributed to low-and middle-income countries around the world who have been effectively priced out of access to the mRNA vaccines (5) . In partnership with COVAX, the goal is to distribute up to 3 billion doses for global distribution (6) . In late February, Ghana was the first African country to receive doses for administration with Cote D'Ivoire to follow (7) . Despite the laudable goal, the clinical development of this vaccine has been far from uncomplicated. The vaccine candidate was evaluated in several different phase 1/2 and phase 3 studies across the UK, Brazil and South Africa and the data were combined to allow for a more robust estimate of efficacy (3, 8) . The trials had some other changes as well: the initial one dose regimen was expanded to 2 doses; the initial dose was adjusted based on better methods to quantify viral quantity so some recipients received a low dose (1/2 dose) for dose 1 and a full dose for dose 2 while most received 2 equal full doses; the dosing interval was expanded from initial 28 days to up to 12 weeks for receipt of dose 2 (8) . Adults 18 y.o. and older were included in the trials, and the quadrivalent meningococcal conjugate vaccine was used in the control arm. Participants were asked to contact the study team if they developed symptoms at anytime during the study but were also asked to self -collect nasal swabs to monitor for asymptomatic infections. It is important to note that these studies were performed both in the UK and South Africa during a time when new SARS-CoV2 variants had emerged. The top line summary of the pooled results of these studies indicated an esti mated 70% efficacy, but this figure does not capture many important details within the data (8) . First, there was a significant difference in estimated efficacy in the group who received the low dose for dose 1 (90% efficacy) compared to those who received standard dose for both dose 1 and 2 (60% efficacy). The most plausible explanation for this result is that there is some degree of immunity against the vector that is generated by the higher first dose that may interfere with immunogenicity from the 2 nd dose. This has been observed in gene therapy trials using adenovirus vectors (9) . Second, the efficacy against symptomatic infection was much higher than against asymptomatic infection (67% vs. 27%). Third, there was higher estimated efficacy when the dosing interval between doses 1 and 2 was greater than 6 weeks (65% vs. 53%). A subsequent study demonstrated when the interval between dose 1 and dose 2 was closer to 12 weeks that the estimated efficacy climbed to about 80%(10). However reduced efficacy results from South Africa, where a new variant, known as 20H/501Y.V2 or B.1.351, generated concern. . The data released as a pre-print and reviewed in the Financial Times reported 10% protection against mild to moderate COVID-19 infection in a cohort of HIV-negative young adults (11) . It is important to note that these recipients received two standard doses 4 weeks apart, which based on the prior studies would have been a regimen that offered the lowest levels of efficacy. However, these caveats on the low efficacy estimates were not raised in the pre-print or the lay press, and South Africa has already announced they will procure additional vaccine from other companies as part of their national strategy against COVID-19 (12) . The study evaluating dosing interval also reported 100% efficacy against hospitalization and severe COVID-19 infection (10) . Trials are underway in the US, but they are being performed using the sub-optimal dosing parameters of 2 standard doses and a dosing interval of 4 weeks (NCT04516746) (13) . There are significant advantages that this version of the vaccine would offer. The storage requirements are quite forgiving: it can be kept at 2-8°C for up to 6 months, which means it could be distributed very broadly to many office and non-healthcare settings around the world (13) . The very low production cost would rectify the tremendous inequity that currently exists between rich countries and the rest of the world. With more than 110 million global cases and more than 2.5 million deaths at the time of writing, a vaccine with 60-70% efficacy would have a tremendous impact on control of COVID-19 infections in low-and middle-income countries(14). What does this all mean for the Oxford/AstraZeneca COVID-19 vaccine as an option going forward? With the nuanced results and the need to modify the dosing regimen, the vaccine still needs further study with an optimized dosing interval. It is very possible that a low dose/high dose combination spaced 12 weeks apart with an optimized SARS-CoV2 Spike sequence that targets some of the mutations in the new variants could yield efficacy estimates that rival those of the mRNA vaccines. Given the low production cost and promise for global settings, it would be unjust to abandon this vaccine without fully studying every option to maximize its efficacy. If the product fails after attempts to increase efficacy, then a decision to move on to other options would be warranted. This version of the vaccine is like the Oxford/AstraZeneca vaccine in that it utilizes a recombinant adenovirus vector expressing the SARS-CoV2 Spike protein. This vaccine differs from the Oxford/AstraZeneca vaccine because this is not a chimpanzee strain but rather an adenovirus 26 strain that can circulate in its natural form. The Adenovirus 26 platform was previously used to create a highly efficacious Ebola virus vaccine that was granted approval by the European Medicines Agency to allow for rapid distribution in the event of a future Ebola outbreak (15, 16) . On February 27, this version of the vaccine was recently granted an EUA by the FDA after review of phase 3 trial results (17) . Phase 1/2 studies demonstrated that this vaccine offered significant antibody levels and neutralization titers with only one dose (18) . This presents a tremendous advantage to quickly achieve protection across a population. In addition to the single dose, there are some other practical advantages to this version of the vaccine. It is provided as a multi-dose suspension that does not need to be reconstituted, so it can be simply drawn up and administered. It is stable at conventional refrigerator temperature (2-8°C) for longterm storage and for 6 hours after being drawn into a syringe and 2 hours at room temperature (19) . While there is still a 2-dose phase 3 study that is still ongoing, the results of the 1-dose phase 3 study were included in the FDA briefing document (19) . Over 40,000 participants were included, with about 14,000 being over 60 y.o. and just less than half having co-morbidities. After excluding over 4000 participants for being SARS-CoV2 positive by PCR and/or serology, 39,300 were included in the perprotocol analysis. Since the trial was performed in the US, Latin America and South Africa, there was considerable racial and ethnic diversity: 17% reported as Black or African-American race and over 40% as Hispanic or Latino ethnicity. The overall vaccine efficacy against moderate to severe COVID-19 infection was 66% (173 cases in vaccinees vs. 509 in placebo recipients), with virtually identical results in the 18-59 y.o. and over 60 y.o. cohorts. Efficacy was a bit higher in the US (72%) compared to South Africa or Latin America (64% and 61% respectively). Sequencing of isolates from South Africa confirmed that 95% of cases were due to the prevailing variant strain, so the 64% efficacy should represent a realworld estimate of its performance. As the severity of infection increased, so too did the vaccine-induced protection: 85% against severe/critical COVID-19 (as defined by the FDA: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developingdrugs-and-biological-products-treatment-or-prevention) and 100% against hospitalization and lifethreatening infection. There were 7 COVID-19-related deaths and all occurred in placebo recipients. An interesting sub-analysis included in this study was estimated efficacy against asymptomatic infection: only 12-22% within the first 29 days after vaccine but 59-74% after day 29. In all, these results support the overall efficacy of this vaccine. Based on these results, South Africa has paused its plans to administer the Oxford/Astra Zeneca vaccine and instead has moved forward with distributing the Janssen/Johnson & Johnson COVID-19 vaccine to their healthcare workers (12) . vitro (Figure 2) . Spike protein that is produced by these infected cells is collected, concentrated and purified into antigen to be administered as a vaccine. The antigen is combined with a proprietary adjuvant that is derived from saponin to help increase immunogenicity with less antigen (called dose-sparing)(23). Baculovirus expression systems are commonly used in scientific research to produce recombinant purified proteins. This technology was used previously to create a highly efficacious Hepatitis E virus vaccine candidate (24) , and Novavax has used or is using this platform to create vaccine candidates against Middle-East Respiratory Syndrome (MERS), Respiratory Syncitial Virus (RSV) and Influenza(23). When considering future vaccine supply, it is important to note that the company has never had an FDA-licensed vaccine product. Phase 1/2 studies with this vaccine candidate evaluated several different number of doses, antigen level and dose interval combinations (25) . These studies demonstrated that 2 doses of 5 ug and 25 ug combined with adjuvant administered 21 days apart offered antibody levels and neutralization titers that were robust and comparable to those found in convalescent serum from laboratory-confirmed COVID-19 recovered volunteers. The lower dose of 5 ug offered a much better side effect profile than the 25ug dose and further allows the company to produce more doses of vaccine with less antigen. Phase 3 studies using this regimen of 2 doses of 5 ug 21 days apart have completed enrollment, one with 15,000 participants in the UK and one with 30,000 participants in the US and Mexico(23). At the time of writing, some limited efficacy data was available from sources provided by the company (22, 23) . In the UK phase 3 study, the first interim analysis was based on 62 cases, 56 in the placebo group and 6 in the vaccinated group, which equates to an estimated vaccine efficacy of 89% (22) . Sequencing studies demonstrated that the UK variant was increasingly observed over the course of the study, and the vaccine appeared to offer 85% protection against the B.1.1.7 variant. Interim data from the US and Mexico study is not yet available. To their credit, Novavax amended their original phase 3 study protocol to allow for crossover dosing of all participants(23). This is the first trial to address the ethical concerns that many have expressed regarding the COVID-19 vaccine placebo arms. The crossover design maintains blinding while collecting safety and efficacy outcomes data. Participants receive extra inoculations but receive active vaccine as a volunteer (26) . A separate phase 2b study from South Africa is worth discussing because there are some very interesting observations to note(22). There were a total of 4400 participants enrolled in this trial . While the overall efficacy among all participants against any COVID-19 infection was just below 50%, the estimated efficacy in HIV-negative participants with mild, moderate and severe disease was about 60%. Over 90% of the isolates identified in this study were the South African, B.1.351 variant, so this level of protection is better than or comparable to those previously described vaccine candidates. This trial also included about 1500 participants with evidence of prior COVID-19 infection. While it is not clear from the data available now if this can be confirmed, it is hypothesized that these individuals were infected with isolates prior to the emergence of the new prevailing South African strain. The observations suggest that prior immunity may not fully protect against these new strains and that vaccine may have some role in optimizing protection. These data are quoted from the Novavax press release and not otherwise available for further evaluation, so some caution must be taken before fully accepting these claims. Similar to the Janssen/Johnson & Johnson vaccine, this Novavax COVID-19 vaccine also has some practical advantages that make it appealing: It can be stored at 2-8°C refrigerator temperature; It is provided as a liquid in 10-dose vials that can be drawn up and administered(23). These attributes are well suited to existing vaccine infrastructure, which means this vaccine could be easily introduced into settings that currently offer vaccines and others that are designed to increase access to rural and/or underserved areas with populations at high-risk of complications. The biggest challenge is the scale up of production to meet demand. Novavax has been building their capacity over the last several months in anticipation of vaccine authorization, partnering with other US-based firms to assist with antigen and adjuvant production(23). Novavax is contracted to deliver 110 million doses by the 3 rd quarter of 2021, but their estimated global capacity with new agreements may reach 2 billion doses per year. These are highly ambitious figures, but even delivery of a fraction of these doses will be a meaningful addition to global supply. There is specific mention of partnering with producers in India, but there is no specific mention of intent to distribute to low-and middle-income countries or suspending intellectual property claims to facilitate low cost production. While the expected authorization of all of these vaccines represent major steps in the progress towards ending this pandemic, there are still many issues that should temper enthusiasm. Domestic and global supply continues to be a major limiting factor. As mentioned in the previous commentary, the numbers needed to vaccinate to achieve the herd immunity estimate of 70-80% of the global population number in the billions of doses (2) . This is unprecedented scale and will require the expected supply of all the available vaccine plus many others not discussed. As pertinent as global supply is the issue of ongoing global inequity in vaccine availability. Rich countries continue to procure more and more vaccine doses, which effectively limits vaccine access for most of the rest of the world. COVAX is trying to address this inequity, but most countries will not receive significant doses of vaccine until well after 2021 (27) . Certain populations like children, older adults or those with immunocompromise may respond more robustly to certain formulations of vaccine than others. With the introduction of several new formulations of vaccine, each representing a new innovation in vaccine design and production, optimism about control of the pandemic grows. However, challenges related to production, supply, and egalitarian distribution should temper this enthusiasm and reinforce the concept that this will need to continue to be a process involving researchers, public health officials, industry partners and regulatory agencies. In the meantime, the public needs continued vigilance adhering to public health measures of universal masking and social distancing to limit spread of the virus. Public health and industry representatives need to continue measures to maximize delivery of vaccine to the general population and research to determine which vaccines or combination of vaccines will provide long-lasting robust immunity against SARS-CoV2. Herd immunity -estimating the level required to halt the COVID-19 epidemics in affected countries The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning? Clin Ther Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca As COVID-19 vaccines emerge, a global waiting game begins Working for global equitable access to COVID-19 vaccines 2020 Vaccine Roll-Out Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Immune Responses to Viral Gene Therapy Vectors Single -dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Oxford/AstraZeneca jab fails to prevent mild and moderate Covid from S African strain, study shows. Financial Times South Africa Rolls Out J&J Covid-19 Vaccine to Healthcare Workers Wall Street Journal COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine Vaccine for the Prevention of COVID-19 Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands barda-to-provide-merck-with-funding-to-expand-mercks-manufacturing-capacity-for-covid-19-vaccinesand-medicines/ 22. Novavax COVID-19 Vaccine Demonstrates 89 Testimony of John Trizzino, Executive Vice President Safety and efficacy of a recombinant hepatitis E vaccine Phase 1-2 Trial of a SARS Recombinant Spike Protein Nanoparticle Vaccine The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials Poor Countries Fall Behind In Race To Reserve COVID-19 Vaccine. Goats and Soda Warp Speed for COVID-19 Vaccines: Why are Children Stuck in Neutral? The author would like to thank Andi Shane, MD, MPH for her thoughtful comments and feedback on the content of the manuscript, as well as colleagues within the Division of Infectious Diseases at the Ann & Robert H. Lurie Children's Hospital of Chicago for their camaraderie and ongoing efforts to serve the community during this pandemic.